May 8 is World Ovarian Cancer Day, a time when advocates around the world raise their voices to increase awareness, support those affected, and…
Gynecological cancer
The U.S. Food and Drug Administration (FDA) has granted fast track status to a combination of lunresertib and zedoresertib — two therapies in development by…
In an early clinical trial, people with certain advanced or treatment-resistant gynecological cancers showed strong responses to the experimental therapy mocertatug rezetecan (Mo-Rez), according…
A new regimen using the immunotherapy Keytruda (pembrolizumab) has been approved in the European Union for use by certain people with hard-to-treat gynecological…
A test that uses artificial intelligence (AI) to analyze genetic data from a vaginal swab can detect endometrial cancer with high diagnostic accuracy, a new…
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to the experimental therapy ZW191 as a potential treatment for hard-to-manage ovarian cancer.
Overt Bio said it established a clinical advisory board to support the development of OVT-101, its lead investigational CAR T-cell therapy for ovarian cancer,…
Researchers have developed a new cell therapy that aims to treat endometrial cancer by targeting cancer cells while also depleting immune cells that help protect…
A combination of two immune-modulating treatments, Lymphir (denileukin diftitox) and Keytruda (pembrolizumab), was well tolerated in an exploratory clinical trial of people with hard-to-treat…
A low dose of alnodesertib added to standard chemotherapy significantly reduced the likelihood of disease progression among people with platinum-resistant high-grade serous ovarian carcinoma (HGSOC)…
